Lyudmila Georgieva, Ezam Uddin, Jacqueline Chan, Faidra Partheniou, and Graham Speight (Oxford Gene Technology (OGT), Oxford, UK)
The MTC generated is dependent on the size of each panel. Overall, both workflows generated very good coverage. The MTC generated with the 1-day protocol is >80% of the MTC generated with the standard protocol. The % change is consistent for all panels.
All panels meet the following uniformity specifications: >99% of bases covered at >20% of the mean (after de-duplication). This permits the reliable detection of more complex rearrangements (i.e.) indels and ITDs.
The SureSeq Core MPN panel has been validated with samples from the National Institute for Biological Standards and Control (NIBSC) and we have shown the accurate detection of JAK2 V617F is possible down to the 1% Variant Allele Frequency (VAF) level at a de-duplicated read depth of >1000x (Table 2).
Mutations in the CEBPA and FLT3 genes are among the most common molecular alterations in AML. Sequencing of the CEBPA gene is often hampered by a repetitive nucleotide sequence and a very high GC-rich content. Genes such as FLT3 ITDs are challenging to target because they are by nature repetitive, can be long and are generally masked in most panel designs.
Using the enhanced workflow we were able to reliably detect single nucleotide variants (SNVs) as well as insertions (5 bp insertion in JAK2 exon 12 and CALR exon 9) and deletions (5 bp deletion exon 12 JAK2 and 52 bp deletion CALR exon 9).
SureSeq™: For Research Use Only; Not for Diagnostic Procedures.
* Samples kindly provided by Prof. Nick Cross, (National Genetics Reference Laboratories - Wessex, UK)
Call +44 (0)1865 856800 Email contact@ogt.com
Send us a message and we will get back to you